Pfizer to shutter vaccines sales business in China

SHANGHAI, April 2 (Reuters) - U.S. drugmaker Pfizer Inc said on Thursday it will cease its vaccines sales operations in China after an import licence for one of its top-selling treatments, the only vaccine it sold in the country, was not renewed.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.